Targacept is a biopharmaceutical company located in Winston-Salem, NC that was founded in 1997 and has 117 employees. They research disorders of the central nervous system by targeting the nicotinic subtype of acetylcholine neurons in the brain. During their first three years, they were a subsidiary of RJ Reynolds and published many articles on the molecular effects of nicotine and the potential of the neuronal nicotinic receptor as a therapeutic target. They currently have five drug candidates in development for conditions like depression, ADHD, and Alzheimer's, and are conducting a Phase II clinical trial of TC-5619 as an adjunct treatment for cognitive dysfunction in schizophrenia.